Researchers tracking nearly 2,000 people from the Diabetes Prevention Program (DPP) have found blood chemicals that can predict who will develop diabetes-related eye, kidney, or nerve damage up to 15 years later. 
This long-term study published in the Diabetologia followed 1,947 participants in the DPP Outcomes Study, using advanced analysis on 353 known metabolites from blood samples. They aimed to spot markers tied to nephropathy, retinopathy, and neuropathy, which are the common microvascular issues in diabetes. 
At follow-up, 572 people had at least one problem: 277 with kidney issues, 194 with eye damage, and 212 with nerve problems.
Metabolites Light Up Specific Risks
Out of 105 metabolites linked to any complication, most targeted just one: 74 for a single issue, 27 for two, and only four for all three. In combined data from all treatment groups, low histidine levels tied to higher kidney damage odds with an odds ratio of 0.75. Low serine worked the same way for kidney issues at 0.69 and for nerve problems at 0.68. These links stayed strong without treatment differences.
Treatment Twists Change the Picture
Some metabolites acted differently based on DPP treatment. Among 36 with interactions, high N-carbamoyl-β-alanine raised kidney damage odds to 1.99 in metformin users. Meanwhile, higher C22:0-sphingomyelin cut nerve damage odds to 0.54 in that group. In lifestyle intervention patients, higher quinolinic acid boosted nerve risk to 1.64. All these results adjusted for sex, race, starting age, BMI, smoking, time followed, and later factors like HbA1c, new diabetes, and kidney function and the patterns still held firm.
Pathways to Smarter Prevention
This work shows each complication has its own metabolite fingerprint alongside some overlaps, urging doctors to study targeted causes beyond general diabetes harm. For clinic use, simple blood tests for histidine, serine, or others could flag high-risk patients early for kidney or nerve protection. Treatment-specific effects mean lifestyle or metformin users might need tailored watches on certain markers. Physicians gain tools to personalize prevention, potentially slowing these silent threats before they hit.